OncoMatch/Clinical Trials/NCT06375187
A Study of GC203 TIL in Advanced Malignant Solid Tumors
Is NCT06375187 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Engineering Tumor Infiltrating Lymphocytes for solid tumor.
Treatment: Engineering Tumor Infiltrating Lymphocytes — A clinical trial to assess the safety and efficacy of engineered Tumor Infiltrating Lymphocytes (TIL) for the treatment of Advanced Malignant Solid Tumors
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Ovarian Cancer
Endometrial Cancer
Cervical Cancer
Breast Carcinoma
Colorectal Cancer
Gastric Cancer
Hepatocellular Carcinoma
Pancreatic Cancer
Cholangiocarcinoma
Esophageal Carcinoma
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: standard therapy
have failed standard therapy (standard therapy is defined as existing guidelines and consensus recommended therapy [including but not limited to chemotherapeutic therapy, radiotherapy, mutation-targeted therapy, immunotherapy, and surgery])
Cannot have received: systemic antitumor therapy
Patients who have received systemic antitumor therapy within 4 weeks.
Cannot have received: allogeneic T cell therapy
Participants who have had a history of allogeneic T cell therapy
Cannot have received: gene engineering autologous cell therapy
gene engineering autologous cell therapy within 1 years
Lab requirements
Blood counts
Absolute Neutrophil Count (ANC) ≥1.0×10^9/L; Absolute Lymphocyte Count (ALC) ≥0.5×10^9/L; Platelet ≥80×10^9/L
Kidney function
Serum Creatinine (Scr) ≤1.5mg/dL (or 132.6μmol/L) or Creatinine Clearance ≥60mL/min; Urinalysis: urine protein less than 2+, or 24-hour urine protein <1g
Liver function
AST/SGOT ≤3×ULN; ALT/SGPT ≤3×ULN; Total Bilirubin (TBIL) ≤1.5×ULN
Patients must have the following hematologic parameters, Coagulation functions and hepatic and renal function: * Absolute Neutrophil Count (ANC)≥1.0×10^9/L; * Absolute Lymphocyte Count(ALC)≥0.5×10^9/L; * Platelet≥80×10^9/L； * International Normalized Ratio（INR）≤1.5×ULN; * Activated Partial Thromboplastin Time（APTT）≤1.5×ULN; * Serum Creatinine (Scr)≤1.5mg/dL (or 132.6μmol/L) or Creatinine Clearance≥60mL/min * Urinalysis: urine protein less than 2+, or 24-hour urine protein <1g; * Alanine aminotransferase(AST/SGOT) ≤3×ULN; * Alanine aminotransferase (ALT/SGPT) ≤3×ULN; * Total Bilirubin(TBIL)≤1.5×ULN；
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06375187 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic antitumor therapy, allogeneic T cell therapy, gene engineering autologous cell therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages